Clinical Trial Update: A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial of poziotinib in EGFR or HER2 activating mutations across advanced malignancies was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Glioblastoma Multiforme
• Solid Tumor

Drugs mentioned

• Poziotinib (poziotinib)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Breast Cancer, Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-03-13